Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SEPN
SEPN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SEPN News
Latest Wall Street Rating Updates
May 01 2026
CNBC
Trump Extends Ceasefire with Iran Amid Market Volatility
Apr 22 2026
CNBC
Trump Extends Ceasefire with Iran Amid Market Volatility
Apr 22 2026
Newsfilter
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
Apr 21 2026
CNBC
Amazon Launches GLP-1 Weight Loss Program
Apr 21 2026
Newsfilter
Septerna, Inc. Q4 Earnings Exceed Expectations
Mar 09 2026
seekingalpha
Septerna Reports Positive Phase 1 Results for SEP-631 in Mast Cell-Driven Diseases
Mar 02 2026
NASDAQ.COM
Positive Phase 1 Results for SEP-631 in Chronic Urticaria
Mar 01 2026
Newsfilter
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
Feb 02 2026
Benzinga
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
Jan 09 2026
renaissancecapital
Septerna Appoints Mark A. Wilson as Chief Legal Officer to Enhance Governance
Jan 08 2026
Globenewswire
Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street
Dec 23 2025
Benzinga
Septerna CEO to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Dec 17 2025
Globenewswire
Wells Fargo Raises Rating on Septerna (SEPN)
Nov 15 2025
NASDAQ.COM
Wells Fargo Boosts Septerna Rating to Overweight and Increases Price Target to $28
Nov 14 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Septerna, Increases Price Target to $30
Nov 11 2025
Benzinga
Show More News
